{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 0.9,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Amendment Summary Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "13",
        "sectionTitle": "PROTOCOL AMENDMENT SUMMARY OF CHANGES",
        "description": "Reference to the summary of changes for Amendment 6"
      },
      {
        "id": "ref_2",
        "name": "Signatures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "14",
        "sectionTitle": "Signatures",
        "description": "Reference to the location of required sponsor signatures"
      },
      {
        "id": "ref_3",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Exclusion Criterion No. 1",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference to permitted exceptions for prior therapy"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Progression detected by bone scan at an unscheduled visit prior to week 25 will require the same criteria for documentation of disease progression as week 13 with a confirmatory scan at least 6 weeks later or at the next scheduled scan.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Protocol-specified Documentation for Radiographic Evidence of Disease Progression",
        "pageNumber": 17
      },
      {
        "id": "annot_2",
        "text": "May not have received any growth factors within 7 days or blood transfusions within 28 days prior to the hematology values obtained at screening.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Exclusion Criteria (Criterion 11)",
        "pageNumber": 19
      },
      {
        "id": "annot_3",
        "text": "Once randomized at day 1, subject must maintain ADT with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist during study treatment or have a history of bilateral orchiectomy.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Inclusion Criteria (Criterion 5)",
        "pageNumber": 18
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "5.1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-04-18",
        "description": "Current version incorporating Nonsubstantial Amendment 6",
        "amendmentNumber": "Nonsubstantial Amendment 6"
      },
      {
        "id": "ver_2",
        "versionNumber": "5.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-31",
        "description": "Previous substantial amendment",
        "amendmentNumber": "Substantial Amendment 4"
      },
      {
        "id": "ver_3",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-11-10",
        "description": "Original Protocol",
        "amendmentNumber": "Original"
      }
    ],
    "summary": {
      "referenceCount": 3,
      "annotationCount": 3,
      "versionCount": 3
    }
  }
}